Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01390220
Recruitment Status : Terminated
First Posted : July 8, 2011
Last Update Posted : March 19, 2018
Information provided by (Responsible Party):
Proximagen, LLC

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 2017
  Study Completion Date : No date given
  Certification/Extension First Submitted : March 15, 2018